Articles

Roche’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.

European Commission approves faricimab for treatment of wet AMD, DME

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of 

Researchers found that the rate of visual decline increased significantly in patients with age-related macular degeneration during the COVID-19 lockdown who were followed over time.

Suspension of AMD treatment during the COVID-19 pandemic resulted in increased rates of vision loss

LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring frequent anti-VEGF injections. Interim data anticipated throughout 2023.

LUNA: First patient dosed with Ixo-vec in Phase 2 trial for treatment of wet AMD

Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.

PHOTON, PULSAR trials: Aflibercept meets primary endpoints in safety, efficacy

The U.S. Food and Drug Administration has approved Coherus’ ranibizumab-eqrn (Cimerli) as an interchangeable biosimilar for all five indications of Lucentis.

FDA approves interchangeable ranibizumab biosimilar from Coherus BioSciences

Videos

Nancy Lurker, CEO of EyePoint Pharmaceuticals, shares the 12-month safety data from the DAVIO trial, investigating EYP-1901 for the treatment of wet age-related macular degeneration (AMD) and nonproliferative diabetic retinopathy.

DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden

According to EyePoint Pharmaceuticals, the clinical trial is reviewing EYP-1901, an investigational sustained delivery anti-vascular endothelial growth factor (anti-VEGF) treatment for wet age-related macular degeneration (wet AMD).

First patient dosed in Phase 2 DAVIO trial for wet AMD

At ASRS 2022 in New York City, New York, Rishi Singh, MD, is presenting, “12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert Insert for nAMD: The DAVIO Trial.” The Phase 1 trial showed a reduction in treatment burden over 12 months as well as a favorable safety profile.

DAVIO trial: 12-month results show favorable safety profile, reduced treatment burden in patients with nAMD

Investigators from Thailand took a close look at retinal fluid fluctuations in Thai patients with wet age-related macular degeneration (AMD) and devised a better way to measure the fluctuations in the central subfield thickness (CST). 

TOWER study: A new index to measure retinal fluid fluctuations in the retina in wet AMD

Treatment with faricimab in patients with neovascular AMD achieved improvements in the visual acuity, central subfield thickness, and pigment epithelial detachments.

Wet AMD